Expert Viewpoints
Expert Viewpoint June 2007
Myron S. Cohen, MD, discusses how routine male circumcision may profoundly impact the transmission of HIV.
Judith S. Currier, MD, MSc, discusses how the GRACE study will address questions related to HIV treatment in women.
Joel E. Gallant, MD, MPH, offers perspective on the approval of fixed-dose tenofovir/emtricitabine/efavirenz—the first 1-pill once-daily antiretroviral regimen.
Karen L. Lindsay, MD, discusses aims and scope of the Ribavirin Pregnancy Registry for evaluating outcomes of pregnancies exposed to ribavirin either by direct maternal exposure or by indirect paternal exposure.
W. David Hardy, MD, discusses the history of the treatment interruption strategy for antiretroviral therapy and warns that this strategy overlooks a critical part of the equation–HIV itself.
Ann O'Leary and Greg Millett of the Centers for Disease Control and Prevention in discussing the role of bisexual men in the spread of HIV note that little is known about the sexual risk behaviors of bisexual men, making the absolute risk from this population difficult to estimate.
Jeanne Marrazzo, MD, MPH discusses the current epidemic of syphilis among HIV-infected patients and prevention and management techniques important for physicians who treat these patients.
William Powderly, MD, answers the question: Should antiretroviral guidelines be updated to reflect recent insights into strategies that maximize the chance of achieving virologic suppression with novel agents?
James McIntyre, MD, recounts the controversy surrounding the use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1 and discusses current data for different regimens and their place in the treatment spectrum in resource-poor countries.
David A. Fiellin, MD, discusses current data available regarding the use of buprenorphine in opioid-dependent HIV-infected patients, and highlights the importance for integrating care for opioid dependence into the management of HIV-infected persons.
Mark Wainberg, PhD, highlights key issues regarding the incidence of transmission of multiply drug-resistant HIV and the impact of viral mutations on viral replication capacity. He also discusses antiretroviral strategies for treating patients with highly resistant virus.
Joel E. Gallant, MD, MPH, reviews the renal safety of tenofovir, and discusses whether recent data should influence the clinical use of this agent
William A. O'Brien, MD, MS, discusses the circumstances surrounding the case, potential explanations for the unusual presentation of rapid progression and the important lessons learned from this case.
Ben Cheng, MS, shares his thoughts on the public health impact of the publicity surrounding this case and outlines potential shortcomings of the US health system that were brought to light by this case.
Laura P. Svetkey, MD, reviews the burden of hypertension in HIV-infected patients, and highlights key issues regarding the classification and management of hypertension in HIV-infected patients.
Lynda Anne Szczech, MD, MSCE, discusses key issues regarding prevalence, screening, diagnosis, and treatment of renal disease in HIV-infected patients, and the need for further clinical research in this area.
Stephen L. Becker, MD, reviews a personal selection of the most clinically significant developments in the HIV/AIDS field in 2004.
Joel E. Gallant, MD, MPH, discusses improvements in the convenience, potency, tolerability, and toxicity of current antiretroviral regimens when compared with earlier regimens, and on the basis of these advancements he proposes several reasons to consider earlier initiation of antiretroviral therapy.
Joseph J. Eron, Jr, MD, discusses recent consensus guidelines on the use of enfuvirtide, and outlines his own approach to evaluating which patients might benefit from the inclusion of enfuvirtide in their new regimen.
Daniel R. Kuritzkes, MD, presents a personal selection of the most clinically significant developments in HIV research during the past year.
Joel E. Gallant, MD, MPH, responds to frequently asked questions regarding the failure of triple-NRTI regimens and addresses issues related to their potential causes.
Alexandra M. Levine, MD, reviews recent data on therapeutic regimens and the role of concomitant HAART in patients with AIDS-related lymphoma.
Stephen L. Becker, MD, reviews what's changed in the latest DHHS guidelines on the use of antiretroviral agents, as well as some surprising omissions
Richard E. Chaisson, MD, reviews progress towards improving access to anti-HIV medications in resource-poor countries
William A. O'Brien, MD, MS presents a personal selection of the most clinically significant developments in HIV research during the past year, and discusses their implications for day-to-day patient management
Joel E. Gallant reviews new guidelines from the International AIDS Society-USA and offers a clinician's perspective on their usefulness in patient management
|
Featured Content
Interact with Eric S. Daar, MD, in a new Virtual Presentation of clinical case scenarios.
Paul E. Sax, MD, discusses the latest data regarding when to start antiretroviral therapy.
Martin Markowitz, MD, discusses recent data involving the use of integrase inhibitors.
|